If anyone needs evidence of the vast gulf that exists between the hype and the reality of gene therapy, he can find it in the contrasting fortunes of Neurogene and Sangamo, two companies at the forefront of this sector. The former, established just a year ago, has just closed a Series A Bond sale worth nearly $70 billion to support the therapies it is creating for neurological diseases.  The latter, which has been doing its own research for 20 years, has just lost a third of its stock market value — because it still can't find a winning formula. Progress is certainly being made in gene therapy.  Sangamo's latest clinical trials may have prompted the brutal sell-off on Wall Street.  But they also suggest that the company has broken new ground by achieving "in-body" gene-editing, news that would cheer researchers everywhere. The FDA, which recently approved a string of gene therapy treatments, is certainly on...(Read Full Article)